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Abstract 
Objective 
Acute Lower Limb Ischemia (ALLI) is a serious condition where an artery of the lower limb 
is occluded resulting in impaired blood flow. The condition may lead to death and amputation 
and require urgent medical care.  
Aim 
The purpose of this study was to describe the early chain of care of ALLI patients with 
particular emphasis on early detection and the use of Emergency Medical Services (EMS) as 
well as administration of Low Molecular Weight Heparin (LMWH).  
Methods 
The study included 108 patients for whom medical records at the Sahlgrenska University 
Hospital were reviewed. All patients treated with a main diagnosis of I74.3 according to ICD-
10 fulfilled inclusion criteria.   
Results 
Patients transported to the Emergency Department (ED) by EMS differed from those who 
were not in several ways. They were 8.5 years older. A history of congestive heart failure and 
atrial fibrillation/flutter was more frequent among those who used EMS whereas the opposite 
was found with regard to previous Peripheral Arterial Disease (PAD). 
 
The median time from hospital arrival to first physician contact was 52 minutes when ALLI 
was suspected by the EMS personnel and 102 minutes if not (p=0.017). The time from 
symptom onset to revascularization was shorter when the EMS personnel suspected ALLI, 17 
hours compared to 56 hours when not (p=0.011). Administration of LMWH in the ED tended 
to be associated with improved outcome.  
Conclusion 
 4 
Patients who use EMS were older and had a more severe co-morbidity than those who did 
not. Early detection of ALLI by the EMS personnel was associated with a shorter delay to see 
a physician and to revascularization. Early treatment with LMWH might be associated with 
improved outcome.   
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Introduction 
Background 
Acute Lower Limb Ischemia (ALLI) is a form of Peripheral Arterial Disease (PAD) that 
requires immediate medical attention. Other forms of PAD are Intermittent Claudication (IC), 
and Critical Limb Ischemia (CLI). PAD is very common, particularly in the elder population. 
[1].  
 
When present, ALLI is a serious medical condition resulting in chronic damage to the 
affected limb or amputation. ALLI is defined as an urgent loss of blood circulation in the 
lower extremity, resulting in threatened limb viability[1].  
Pathophysiology and etiology 
Acute lower limb ischemia has several etiologies. The most common etiologies are; 
thrombosis in situ in the affected artery [2], embolism originating from the heart [3] or 
dissection or trauma. The clinical consequence is an occluded artery, resulting in reduced or 
depleted blood circulation in the affected extremity [3]. Thrombosis is commonly formed 
arterial segments with pre-existing atherosclerotic plaques, leading to a sudden worsening of 
an already present PAD, often referred to as Acute-On-Chronic (AoC). Thrombosis may also 
occur in previous arterial reconstructions, in arterio-venous malformations, and in popliteal 
aneurysms. Atrial flutter or atrial fibrillation is the main cause to cardiac embolisms. In these 
cases the thrombus is commonly formed in the auricles of the heart, travelling along the 
bloodstream as an embolus until the lumen narrows and the embolus occludes the vessel. 
Another reason for cardiac embolism is a recent myocardial infarction, where the hypokinetic 
myocardium allows for blood congestion and embolism formation [4]. A less common 
genesis for embolism is atrial myxoma and paradoxal embolism[5, 6].  
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Ischemia is a biochemical reaction due to absence of oxygen. As a consequence of oxygen 
deficit, anaerobic metabolism is commenced in the cells of the affected tissue. Lactic acid is 
produced by anaerobic metabolism and due to failing ATP-reliant ion transport pumps 
calcium accumulates in the cell. High intracellular calcium levels generate phospholipases 
and other enzymes degrading the cell components. As the cell membrane is damaged by the 
release of phospholipases more cytotoxic substances enter the cell and the mitochondria 
deteriorate, leading to apoptosis of the cell. If apoptosis is not present the cell may also 
necrotize [7, 8].  
 
As an effect of ischemia an imminent immune response will be present, causing a major 
inflammatory reaction in the hypoperfused tissue. Cytokines and other metabolites released 
from the necrotic cells attract inflammatory cells to the location of the ischemic reaction. An 
adverse effect of the inflammatory response is edema, which in severe cases result in 
increased pressure within one or several compartments of the limb. The increased interstitial 
pressure leads to a further lowered capillary perfusion of the tissue, and thereby increased 
ischemia. This condition is referred to as compartment syndrome and needs immediate 
fasciotomy to release pressure [8-10]. In severe cases rhabdomyolysis may occur leading to 
kidney failure due to high blood levels of myoglobin, a remnant of shattered muscle cells 
[11]. Compartment syndrome is common after reperfusion in severe limb ischemia and is then 
referred to as reperfusion syndrome [12]. 
Epidemiology and risk factors 
There is very little consistent data available regarding the frequency of ALLI. ALLI has been 
reported to be a rather rare condition, and different data sources report various incidence and 
prevalence. However, previous studies have shown that approximately 14/100 000 are 
affected by Acute Lower Limb Ischemia yearly [1]. The National Registry for Vascular 
 7 
Surgery reported 820 revascularization procedures for ALLI during 2013[13]. The reported 
incidence of other forms of PAD differs substantially between studies. In a population in the 
age of 55 and above, 16 % of individuals suffered from any form of PAD in the lower 
extremities. A German study has shown that 19.8 % in a male population suffered from PAD. 
A Swedish study has shown that 4.1 % of individuals aged 50-89 suffered from a 
symptomatic chronic PAD in the lower extremities [14]. The most recently reported Swedish 
data states that almost one fifth of individuals >60 years of age suffers from any sort of PAD 
[15].  
 
As atherosclerosis is a main cause of ALLI, as well as cardiovascular disease and 
cerebrovascular disease these conditions share other risk factors as well. Common risk factors 
for PAD and ALLI are hence diabetes mellitus, smoking, hyperlipidemia, hypertension, 
kidney disease and a previous cardiovascular or cerebrovascular disease [14]. The risk of an 
embolic event is markedly increased by atrial flutter/fibrillation, recent myocardial infarction, 
previous stroke and previous ALLI [1]. According to a study performed in Edinburgh 
smokers have a 3.7 times increased risk of PAD compared to non smokers [16]. 50-80 % of 
patients with PAD suffer from hypertension according to several studies [14]. A British study 
(UKPDS) performed on 3834 individuals without PAD at the time of diagnosis of diabetes 
mellitus type 2 proposed that an increase of HbA1c of 1 % (11 mmol/mol) leads to an 
increased risk of 28 % to develop PAD in the lower extremities [17]. Patients developing 
PAD often suffer from several of the risk factors mentioned above [18].  
Clinical presentation 
ALLI has a varying clinical presentation depending on etiology, severity and progress of the 
process. ALLI of embolic genesis commonly presents as a pale, painful and numb extremity 
[19]. The debut is often sudden, and patients can remember the time of onset very accurately. 
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There are several clinical symptoms coherent with ALLI. A common presentation of 
symptoms is referred to as “The six P’s”, denoting Pain, Pallor, Paresthesia, Poikilothermia, 
Pulselessness, and Paralysis [3, 10]. Patients have a lowered Ankle-Brachial Index (ABI), a 
simple examination indicating a lowered blood pressure in the affected limb due to arterial 
obstruction [20]. In certain cases the syndrome is presented only by paralysis and numbness 
in the affected limb and may therefore be incorrectly diagnosed as cerebrovascular or spinal 
disease [21]. In some cases cyanosis may be present. For patients with thrombosis in situ the 
progress is slower and more sub-acute. Among these patients, it is common with paresthesia 
and intact motor function and they do not commonly present with all six P’s [3].  
Figure 1 - SVS/ISCVS acute limb ischemia classification.  
 
A clinical scale for classification is proposed in 1997, known as the SVS/ISCVS (Society of 
Vascular Surgery/International Society of Cardiovascular Surgery) acute limb ischemia 
classification, fig. 1, is used in clinical practice [22]. The scale consists of four steps assessing 
the risk of limb damage and thereby need of acute medical care. Class I is a viable limb with 
no signs of, or symptoms such as motor or sensory loss. Class II consists of two grades, class 
IIA, which is a marginally threatened limb showing mild symptoms, and class IIB which is an 
immediately threatened limb showing a higher grade of symptoms. Class III indicates a limb 
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with major symptoms, such as motor and sensory loss. In a Class III limb the ischemic 
process has resulted in irreversible damage to the affected limb [22].  
 
Treatment and prognosis 
At the emergency department (ED) administration of Low Molecular Weight Heparin 
(LMWH) may prevent further propagation of the thrombus, and a rapid diagnosis is important 
to ensure a good treatment result of surgery [10]. There are two major revascularization 
interventions clinically used: catheter-directed thrombolysis and surgery [23]. Thrombolysis 
is performed by intravasal administration of a tissue plasminogen activator, alteplase (rTPA) 
[24]. The intervention is performed by using endovascular techniques to place a catheter 
within the occlusion and at this site administer rTPA. Normally the catheter is inserted into 
the vessel via the femoral artery on the contralateral side but this depends on the location of 
the thrombus in the extremity[25, 26]. Surgical thrombembolectomy is normally performed 
by using a Fogarty balloon catheter. Following a surgical cut-down and arterial cross-
clamping the artery is entered proximally to the obstruction, commonly in the femoral artery 
[27]. Removal of the thrombus is done by passing the arterial obstruction with the catheter 
and inflating the balloon at the tip of the catheter distally to the thrombus. The balloon is 
inflated until filling the lumen of the vessel. The balloon is then drawn in proximal direction 
along the artery, bringing the thrombus to the location of the arterial incision and making an 
extraction possible. After the thrombus is removed the artery is sutured and blood flow is 
reestablished [1, 10]. The procedure can be performed during local anesthesia. In some cases 
more extensive vascular procedures, such as bypass surgery, is performed [1]. According to 
the STILE-study there was no significant difference between catheter-directed thrombolysis 
and thrombembolectomy in 30-day survival. In patients with ALLI thrombolysis has been 
reported to have a significantly higher amputation-free survival compared to surgical 
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treatment, but no significant difference in several other parameters analyzed [24]. Similar 
results was found in a recent Cochrane report describing no significant differences regarding 
outcome between the interventions [28]. Thereby it may be stated that the prognosis is more 
dependent on the severity and classification of the ischemia rather than choice of intervention 
[1, 24].  
Aim 
 
ALLI is a very serious condition with a high rate of amputation and death among patients. 
Many factors may affect the outcome of treatment in emergency care, and not much research 
has been done on this area. The purpose of the survey was to study the patients who had been 
diagnosed with ALLI and who had undergone thrombolysis, revascularization surgery or 
other treatment. The aim was to describe the early chain of care with emphasis on early 
detection, the usage of EMS and early use of LMWH. The following research questions were 
formulated:  
1. What factors in the early chain of care may affect survival and rate of amputation 
among patients affected by ALLI?  
2. Will early administration of LMWH affect patient outcome regarding death and 
amputation in patients affected by ALLI? 
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Material and methods 
Study design 
The study was a retrospective descriptive cohort study conducted on hospital records for 
patients with a defined main diagnosis of I74.3 according to the International Classification of 
Diseases, 10th revision (ICD-10).  
Time of survey 
The study was conducted on patient records from 2012-01-01 to 2014-12-31. The study was 
conducted in Sept 2015 to Nov 2015.  
Study area 
The study was conducted at Sahlgrenska University Hospital (SU) in Gothenburg and 
Mölndal municipality, Sweden. Sahlgrenska University Hospital consists of three different 
emergency wards, located at SU/Östra, SU/Mölndal and SU/Sahlgrenska. The cardiovascular 
surgery department is located in SU/Sahlgrenska and patients are therefore transported to this 
hospital if invasive interventions are indicated. The Sahlgrenska University Hospital serves 
approximately one million inhabitants in the Gothenburg Region, and serves up to 1.7 million 
people as being the tertiary referral hospital of Western Sweden.  
Inclusion 
Patients were eligible for the study if they;  
1) had been submitted to Sahlgrenska University Hospital,  
2) had a final discharge diagnosis of I74.3 (Embolism and thrombosis of arteries of lower 
extremities) according to ICD-10,  
3) had sought emergency care at one of three EDs at Sahlgrenska University Hospital 
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Exclusion  
Patients were excluded if they: 
1) had been wrongly diagnosed with I74.3,  
2) had primarily sought emergency care at another hospital than one of the EDs at 
Sahlgrenska University Hospital,  
3) had received the diagnosis I74.3 during an outpatient visit or other visit than an ED visit,  
4) had developed ALLI in hospital while treated for other diagnoses. 
 
Data collection 
Data collection was performed by searching the different hospital systems with medical 
records. Patients were identified by using the administrative platform “Elvis” using the I74.3 
diagnosis code. Elvis was also used to determine priority of patients at the ED, the time of 
arrival to the ED for patients not transported by EMS, time to doctor, total time at the ED as 
well as the date of death.  
 
For patients transported by EMS data was gathered from an application known as AmbuLink 
where all major data from the EMS is recorded. In the AmbuLink data concerning symptom 
onset, time of phone call to dispatch center, time of outcall, time of arrival to the patient, time 
of departing with the patient, time of arrival to hospital, as well as vital parameters and 
medical priority was retrieved. Medical treatment, significant symptoms, pain level as well as 
whether EMS staff suspected limb ischemia or not was also retrieved from the AmbuLink.  
 
By using the platform Melior and its applications SIE View and E-Arkiv data regarding the 
hospital stay, treatment and clinical reasoning regarding diagnosis and choice of treatment 
was gathered. Data from the ED was gathered from scanned paper journals according to the 
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RETTS system. The RETTS system is a triage system developed by a Swedish company, 
Pedicare, used by the EMS and EDs in the Västra Götaland region [29].  
Definitions 
All data entered have been defined according to data stated in medical records. In all cases the 
time of symptom onset reported by the patient was used, if available. When a specified time 
of onset wasn’t available in medical records the time of onset has been defined as 12.00 
(noon) at the date of onset. Morning was defined as 08.00, noon as 12.00, afternoon as 16.00 
and evening as 20.00.  
Severe loss of function was defined as persistent neuropathic pain requiring pharmacological 
treatment and/or loss of motor function resulting in reduced walking ability. Loss of function 
has only been reported as “yes” if there are clear medical records of sequelae.  
Statistical methods 
Data was assembled in worksheets using Microsoft Excel 2011. All data analysis were 
performed using the statistics software IBM SPSS Statistics Version 23 (SPSS, Chicago, 
2015). Intergroup comparisons of categorical variables were done using Fishers Exact. The 
non-parametric Mann-Whitney-U test was used for continuous variables. Significance has 
been set to p <0.05.  
Ethics 
The study was carried out within the bound of the Helsinki declaration. The study was 
approved by the regional ethic review board of Gothenburg, D-nr 853-15. To ensure patient 
integrity all files containing social security numbers or other personal information have been 
password protected. Only the author and the supervisor had access to these passwords. In the 
worksheets each patient was allocated a serial number matching a serial number in the data 
files, making identification impossible without the password protected data files.  
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Results 
Enrollment 
Initially 369 patients were identified as matching the diagnosis I74.3 according to ICD-10. 92 
patients where excluded due to diagnosis being registered several times and patients 
appearing multiple times in the database. 44 patients sought emergency care at another ED 
than SU before transported to SU/Sahlgrenska and where therefore excluded. 56 patients 
where inaccurately diagnosed with I74.3 (Embolism and thrombosis of arteries of lower 
extremities) in the medical records. 27 patients where excluded because they did not search 
emergency care or they had a non-acute debut of symptoms despite being diagnosed with 
ALLI. Some patients developed ALLI while being treated for other conditions in hospital; 
these patients were also excluded from the study. 8 patients were excluded from the study for 
other reasons. Such a reason may be that they where not found in the medical records. After 
all exclusions had been performed 108 patients remained and were finally included in the 
study (Fig. 2). 
  
 
 
 
 
 
 
 
 
 
Figure 2 – Flow chart explaining the exclusion procedure. 
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Baseline data and co-morbidity 
The study thus analyzed a total of 108 patients. The patients were divided into two groups to 
facilitate comparison, patients transported by EMS to hospital (EMS) and patients not 
transported by EMS (NON) as shown below in table 1. Of the 107 patients 62 (58 %) patients 
were transported by EMS and 45 (42 %) used other transport. Among the studied patients was 
mean age 76.8 (CI 95%, 74.4 – 79.2) years and 54 (50.5 %) of patients being of male gender. 
Many of the patients had several co-morbidities. More than 50 % of patients included in the 
study suffered from hypertension, PAD or atrial flutter/fibrillation. A large proportion of 
patients were either current smokers (n=23, 21.6 %) or previous smokers (n=36, 35.3 %), i.e. 
more than half of patients (n=59, 56.9 %) had a smoking history.   
 
In the EMS group median age was 82.5 while median age in the NON group was 74 years. 
When comparing the two groups (EMS versus NON) several differences in co-morbidity were 
noted. There were statistically significant differences in the prevalence of congestive heart 
failure (48.4 % vs. 13.3 %, p<0.001), atrial fibrillation (77.4 % vs. 35.6 %, p<0.001), stroke 
(38.4 % vs. 15.6 %, p=0.01), PAD (46.8 % vs. 68.9 %, p=0.03) and previous arterial surgery 
(4.8 % vs. 20 %, p=0.026), table 1. 
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Table 1 – Chart describing patient demographics and comorbidities. Results are described for both 
groups; EMS transported patients and non-EMS transported patients. The percentages for the entire 
group are also displayed. P-values refer to comparison between EMS and non-EMS transported 
patients.  
 
The 30-day overall mortality was 14 %. In patients with a history of stroke the 30-day 
mortality was 29 % compared to 9 % for patients without previous stroke (p=0,011). The 
overall one-year mortality was 33 %. One-year mortality among patients with previous stroke 
was 52 %, compared to 25 % in the non-stroke subgroup (p=0.018). No other significant 
relationships between co-morbid status and ALLI outcome could be found in terms of risk of 
death or amputation during the subsequent 30 days and one year.  
 
 17 
Intervention 
Patients treated with thrombolysis (n=48) had a lower amputation rate at 30-day follow-up 
compared to patients treated with thrombembolectomy (n=39) (n=3 (6.3%) vs. n=5 (12.8%), 
p=0.003). Table 3. In a 1-year follow-up of amputation figures were similar (n=3 (6.5%) vs. 
n=5 (14.3%), p=0.001). All amputations were done within 30 days. Table 3. There are 
apparent differences regarding mortality in 30 days (n=1 (2.1%) vs. n=10 (25.6%), p=0.03), 
table 3. In a 1-year follow up 8.9% (n=4) of patients treated by thrombolysis had deceased, 
while 57.1% (n=20) of patients subject to thrombembolectomy had died (p<0.001) (Table 3).  
LMWH administration 
Concerning patients given Low Molecular Weight Heparin (LMWH) or not there are 
noticeable trends of differences, although not statistically significant. In all four variables 
analyzed during follow-up (amputation and death within 30 days and one year) there were 
differences regarding treatment outcomes as shown in figure 3. In total, 52.6 % of patients 
received LMWH in the ED. At 30-day follow-up 17.6 % of patients that did not receive 
LMWH in the ED had to amputate the affected limb, compared to 7.1 % of patients given 
LMWH (Table 2). Regarding death within 30 days 17.6 % of patients not given LMWH in the 
ED died in relation to 10.7 % of patients given LMWH in the acute phase (Table 2). During 
long-term follow-up at one-year 18.8 % of patients not administered LMWH had to amputate 
the ischemic limb compared to 9.4 % of patients receiving LMWH (Table 2). Among patients 
not receiving LMWH 40.4 % died after one year whereas 26.4 % of patients given LMWH in 
the ED died (Table 2).  
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Figure 3 – Figure displaying different outcome for patients receiving and not receiving LMWH in the 
ED. Percentages are also presented in table 2. 
 
Lead times and EMS diagnosis 
Among EMS patients, the median time from symptom onset to revascularization (surgery or 
thrombolysis), were 23.9 hours while the corresponding time for NON patients were 96.3 
hours p=0.003.  
 
In cases where the EMS staff suspected ALLI the time from arrival in hospital until seen by a 
physician was shorter than when EMS staff did not suspect ALLI (mean 81 vs. 132 minutes, 
p=0.009)(Table 4).  
 
Table 4 – Chart describing the mean and median times until patient see physician depending on 
whether ALLI was suspected in the ambulance.  
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As seen in table 5 the percentage of patients receiving LMWH in the ED is much higher 
among patients where ALLI is suspected in the ambulance, 52.4 % compared to 23.5 % when 
ALLI is not suspected (p=0.008). Among patients suspected of suffering from ALLI by the 
staff at the ED 56.8 % of patients received LMWH while only 9.1 % of patients not suspected 
of having ALLI received LMWH (p=0.003)(Table 5).  
 
In cases (n=42) were ALLI was suspected by the EMS staff the median time from symptom 
onset to revascularization 17 hours compared to 55.8 hours when ALLI was not suspected, 
figure (p=0.011)(Figure 4).  
 
Figure 4 – A diagram displaying the median difference in time (hours) from symptom onset to 
revascularization differing by whether ambulance personnel has suspected ALLI or not.  
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Discussion 
The purpose of this study was to describe the early chain of care in ALLI with particular 
emphasis on early detection, EMS usage and early administration of LMWH. Our data 
suggests that an early suspicion of ALLI within the emergency health-care system is desired 
to achieve satisfactory treatment results. Data also tentatively suggest that early 
administration of LMWH might affect death and amputation outcome positively but this topic 
requires further research. Furthermore patients who used EMS were older and had a more 
severe co-morbidity than patients who did not use EMS.  
 
Naturally there are many factors that might affect the outcome for patients with ischemia in 
the lower extremities. Such factors are age, co-morbidities, smoking, previous PAD and 
degree of limb ischemia. These factors aforementioned cannot not be regulated by the 
healthcare provider in the acute situation. Factors that are modifiable are the timespan to 
diagnosis and intervention, as well as administration of proper medications and choice of 
treatment modality. This study mainly examines the timespan from patient’s symptom onset 
until several different critical points in the chain of care as well as the rate of administration 
of LMWH in the ED and the outcome of LMWH administration. 
 
One factor that stood out significantly was whether EMS personnel had a suspicion of ALLI 
or not. In cases where ALLI was suspected in the ambulance, all lead-times were shortened 
resulting in more rapid diagnosis and a shorter time to revascularization. As time is an 
important factor all efforts that might decrease the time to revascularization are of great 
interest in order to provide good patient safety. Since the EMS personnel gives patients a 
primary priority on scene according to the RETTS-system it is very important that they are 
correctly educated and prepared to suspect conditions like ALLI. Since ALLI is an 
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uncommon condition further education regarding cardinal symptoms of the disease both to 
EMS personnel and to the staff in the EDs is required. The ultimate objective must be that 
even more cases are detected before the patient is examined by a physician in the ED.  
 
A relevant factor is that many of the more severe cases have clear-cut and typical symptoms, 
as mentioned above. These patients are also the ones in greatest need of emergent medical 
care. This might be an explanation to why certain patients receive a higher priority and are 
admitted to revascularization therapy earlier than patients with a less acute onset of 
symptoms. For patients with an Acute-On-Chronic or sub-acute onset the need for an 
immediate revascularization might be less urgent. Despite this, a short time to intervention is 
desirable among all patients to avoid chronic damage and functional loss in the affected limb.  
 
Early administration of LMWH might have a positive effect on both amputation-rate and 
mortality among patients affected by ALLI. With regard to this interesting concept our study 
was underpowered to critically address this research question. Since the outcome varies a lot 
depending on several factors a high spread is likely among the groups. However, as seen in 
figure 3 there seems to be a signal of a more favorable outcome among patients receiving 
LMWH in ED. This finding is especially interesting since it may represent a very simple way 
to improve patient outcome. When revising current literature regarding administration of 
LMWH in the acute phase of ALLI no studies were found providing conclusive data 
regarding patient outcome. LMWH is administered in clinical praxis [1], but lacks satisfying 
results regarding effect in 30-day outcome [28]. More research on this topic is warranted. 
 
In cases where patients are suspected of suffering from ALLI in either before hospital arrival 
or in the ED the percentages of patients administered LMWH are significantly higher 
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indicating that these patients receive an appropriate treatment early in the chain of care 
compared to when ALLI is not suspected. This exemplifies how an early recognition of ALLI 
might directly improve treatment results. 
Limitations 
Possible limitations for this study are that the study was performed at only one medical center, 
and that the study only covers three years. Including other hospitals might have influenced the 
results, as all regional hospitals do not provide acute revascularization treatment at all times. 
Lack of surgical/endovascular treatment resources might lead to longer times until 
intervention. Including more patients, and studying a longer timespan than three years may 
result in a more representative picture, as the condition is not very common. A larger study 
population might enable more conclusive results, as multivariate analyzes in a larger 
population could reveal or discard correlations in a more confident manner.  
 
A retrospective study has disadvantages compared to a prospective study. There are risks of 
information loss due to poor medical records, as well as that all aspects of the situation might 
not have been assessed correctly. A prospective study where all patients are assessed 
according to the SVS/ISCVS classification and randomized for LMWH treatment would 
likely provide a more conclusive result in this respect.  
 
As to assess lead times the retrospective format has fewer disadvantages as times are well 
recorded and provide a good representation of the current chain of care. Despite this some 
loss of information occur due to insufficient patient records.   
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Conclusion 
Several conclusions may be drawn from this study. As to patient characteristics and co-
morbidities it may be concluded that the groups seeking medical care for ALLI by EMS and 
by walk-in differ significantly. Patients using EMS are generally older and suffer from more 
severe co-morbidities, while walk-in patients generally have a history of previous PAD.  
 
Of patients transported by EMS the group were ALLI was suspected had a significantly 
shorter time to see a physician at the emergency department compared to cases were EMS 
personnel did not suspect ALLI. Similar significant patterns may be recognized in time from 
symptom onset to revascularization therapy, as patients are admitted to revascularization 
faster when ALLI has been suspected since the start of the chain of care. These patients are 
also more likely to receive LMWH at the emergency department.  
 
This study also suggests that an early administration of LMWH could lead to beneficial 
outcomes regarding amputation rate and mortality in ALLI. Further studies are needed to fully 
assess this relationship.  
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Populärvetenskaplig sammanfattning 
 
Diagnos och behandling av akut nedre extremitetsischemi och dess effekt på 
behandlingsresultatet 
 
Akut nedre extremitetsischemi är ett allvarligt tillstånd där artärer i benen på patienter har 
blockerats. De vanligaste anledningarna till detta är att en blodpropp bildas lokalt i kärlet, 
eller att en blodpropp lämnar hjärtat och fastnar i kärlet. Att en blodpropp lämnar hjärtat kan 
bero på att patienten lider av förmaksflimmer eller förmaksfladder. När en blodpropp 
blockerar blodkärlet stoppas blodflödet till benet, vilket leder till att vävnad dör efter en tid. I 
akutskedet kan patienten uppleva smärta, förlamning, blekhet, kyla och känselnedsättning i 
benet. Det finns två huvudsakliga metoder för att åtgärda detta, antingen genom att via en 
kateter inlagd i blodkärlet ge ett propplösande läkemedel eller genom att kirurgiskt avlägsna 
proppen.  
 
Målet med denna studie var att undersöka vilka faktorer som kan påverka handläggningstiden 
och därmed behandlingsresultatet, från det att patienten insjuknar i extremitetsischemi till 
dess att kärlet åter blir öppnat och benet återfår blodförsörjning. Målet var också att 
kontrollera huruvida administration av det proppförebyggande läkemedlet Lågmolekylärt 
Heparin (LMWH) påverkar utfallet för patienterna. 108 patienter analyserades genom att följa 
upp journaler från Sahlgrenska Universitetssjukhuset.  
 
Vad man såg var att patientgruppen som sökte vård med ambulans skilde sig från gruppen 
som tog sig till akutmottagningen på egen hand. De som blev ambulanstransporterade var 
generellt äldre och hade andra grundsjukdomar än gruppen som tog sig till akutmottagning på 
egen hand. Av de som tog sig till akutmottagning på egen hand hade fler patienter tidigare 
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problem med dålig blodförsörjning i benen. Man såg också att av de patienter som 
transporterades med ambulans så skiljde sig handläggningen markant beroende på huruvida 
ambulanspersonalen misstänkte akut nedre extremitetsischemi eller ej. Om 
ambulanspersonalen misstänkte extremitetsischemi var tiden tills patient fick träffa läkare 
lägre än om tillståndet ej misstänkes. Detsamma gäller tiden till att blodflödet kunde 
återställas i patientens ben.   
 
För patienter som fick LMWH på akutmottagningen noterades en trend att risken för 
amputation och död minskade gentemot de patienter som inte fick LMWH. 
 
Det kan således konstateras att en tidig klinisk misstanke och tidig korrekt diagnostik minskar 
tiden till kärlintervention avsevärt. Att ytterligare utbilda personal i ambulans och på 
akutmottagningar avseende detta kan sannolikt minska handläggningstiden för fler patienter 
och leda till korrekt utredning och en tidigare behandling. 
 
Avseende administration av LMWH är resultatet ej konklusivt och en större studie bör göras 
på området för att lättare kunna påvisa signifikanta samband. Resultatet pekar dock i en 
riktning som talar för en gynnsam effekt av läkemedlet i akutläget.  
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Tables, Figures and Appendices 
Table 2 – Table displaying the rate of amputation and mortality within 30 days and 1 year depending 
on whether Low Molecular Weight Heparin (LMWH) was administered or not. 
 
Table 3 – Table displaying the rate of amputation and mortality within 30 days and 1 year depending 
on choice of intervention.  
 
Table 5 – Table describing differences in whether patients are administered Low Molecular Weight 
Heparin (LMWH) in relations to ALLI suspicion among ambulance personnel and ALLI suspicion in 
the ED.  
 
 
